Skip to main content
Premium Trial:

Request an Annual Quote

Enzo, Hologic, Grifols Settle Patent Dispute

NEW YORK (GenomeWeb) – Enzo Life Sciences has entered into a settlement and license agreement with Hologic, Grifols, and Grifols Diagnostic Solutions, Enzo disclosed in a recent filing with the US Securities and Exchange Commission.

The agreement settles all outstanding patent disputes among the parties and includes a one-time payment of $14 million to Enzo in exchange for fully paid-up, worldwide licenses to Hologic and Grifols, according to the SEC document.

The dispute centered on Enzo's US Patent No. 6,221,581, covering modified nucleotides for use in diagnostic and therapeutic applications.

In its SEC filing, Enzo said that the settlement and license agreement should not be considered an admission of liability or responsibility, or lack thereof, on the part of Enzo, Hologic, or Grifols. 

In 2017, Enzo had announced that one of its patents at the center of a long-running intellectual property dispute has been found invalid by a federal judge.

Enzo originally sued several companies for allegedly infringing some of its patents. A handful of defendants settled with Enzo in recent years, while others sought to have Enzo's patents invalidated.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.